Carbimazole therapy in the setting of end-stage renal disease and haemodialysis.
Varughese
George I
GI
Department of Endocrinology, University Hospital of North Staffordshire, Stoke-on-Trent ST4 6QG, UK. georgeiv@doctors.org.uk
Tahrani
Abd A
AA
Smith
Jen L
JL
Clayton
Richard N
RN
Hanna
Fahmy W
FW
D000138:Acidosis / Q000150:complications; D000328:Adult; D013956:Antithyroid Agents / Q000008:administration & dosage* / Q000493:pharmacokinetics / Q000627:therapeutic use; D001281:Atrial Fibrillation / Q000209:etiology; D001711:Biotransformation; D002231:Carbimazole / Q000008:administration & dosage* / Q000493:pharmacokinetics / Q000627:therapeutic use; D004058:Diffusion; D004334:Drug Administration Schedule; D006801:Humans; D006980:Hyperthyroidism / Q000150:complications / Q000188:drug therapy*; D007676:Kidney Failure, Chronic / Q000150:complications*; D008297:Male; D008713:Methimazole / Q000493:pharmacokinetics; D011355:Prodrugs / Q000008:administration & dosage* / Q000493:pharmacokinetics / Q000627:therapeutic use; D006435:Renal Dialysis
D013956:Antithyroid Agents; D011355:Prodrugs; D008713:Methimazole; D002231:Carbimazole